MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.69 and traded as high as $2.19. MediciNova shares last traded at $2.10, with a volume of 30,965 shares traded.
Wall Street Analyst Weigh In
MNOV has been the subject of a number of research analyst reports. D. Boral Capital initiated coverage on MediciNova in a report on Monday, December 2nd. They issued a "buy" rating and a $9.00 price target for the company. StockNews.com began coverage on shares of MediciNova in a report on Thursday. They issued a "hold" rating for the company.
Read Our Latest Research Report on MNOV
MediciNova Price Performance
The firm has a market cap of $104.47 million, a price-to-earnings ratio of -10.14 and a beta of 0.84. The stock has a 50-day moving average price of $1.99 and a 200 day moving average price of $1.70.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in MediciNova stock. Jane Street Group LLC bought a new position in shares of MediciNova, Inc. (NASDAQ:MNOV - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,138 shares of the biopharmaceutical company's stock, valued at approximately $30,000. Hedge funds and other institutional investors own 9.90% of the company's stock.
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Read More
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
